Cargando…
PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
Clinical use of doxorubicin (Dox) is limited by cumulative myelo- and cardiotoxicity. This research focuses on the detailed characterization of PhAc-ALGP-Dox, a targeted tetrapeptide prodrug with a unique dual-step activation mechanism, designed to circumvent Dox-related toxicities and is ready for...
Autores principales: | Casazza, Andrea, Van Helleputte, Lawrence, Van Renterghem, Britt, Pokreisz, Peter, De Geest, Natalie, De Petrini, Marzia, Janssens, Tom, Pellens, Marijke, Diricx, Marjan, Riera-Domingo, Carla, Wozniak, Agnieszka, Mazzone, Massimiliano, Schöffski, Patrick, Defert, Olivier, Reyns, Geert, Kindt, Nele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377749/ https://www.ncbi.nlm.nih.gov/pubmed/35149549 http://dx.doi.org/10.1158/1535-7163.MCT-21-0518 |
Ejemplares similares
-
Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma
por: Van Renterghem, Britt, et al.
Publicado: (2022) -
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021) -
TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
por: Tang, Lan, et al.
Publicado: (2021) -
Efficacy of PolyMPC–DOX Prodrugs in 4T1 Tumor-Bearing
Mice
por: McRae Page, Samantha, et al.
Publicado: (2014) -
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)